U.S. FDA Approves Bayer's Electronic Autoinjector for MS Therapy Print E-mail
By Natalie Grover, Pharmacy Learning Network   
Monday, 28 September 2015 23:01
The first electronic automatic injector to deliver a drug for the most common form of multiple sclerosis received approval from the U.S. Food and Drug Administration on Friday.
The injection delivers interferon beta-1 (Betaseron), a disease-modifying drug approved 22 years ago by the FDA for relapsing forms of MS.
    
The new device, called Betaconnect, will be available in early 2016, said Germany's Bayer AG, which developed the injector and sells the drug.
    
Of the 400,000 people living with MS in the United States, about 320,000 people are initially diagnosed with this form of the disorder in which symptoms disappear totally or partially after a flare-up and are followed by a period of stability that can last for months or years.
    
The original device, through which Betaseron is delivered, has its drawbacks. It is mechanically activated and makes a discernible sound during administration, which tends to disconcert patients, according to Amy Ross, former president of the International Organization of MS Nurses.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter